# Efficacy

Keywords: TYSABRI, efficacy, AFFIRM study, clinical relapse, disability progression, RRMS, MRI, Gadolinium-enhancing lesions, EDSS, NEDA

> This page provides detailed information on the efficacy of TYSABRI, including pivotal clinical and radiological data from the AFFIRM study, targeted outcomes for relapsing-remitting multiple sclerosis (RRMS) patients, and key findings from sub-analyses of highly active patient subgroups.

## Details

- [Clinical and Radiological Pivotal Data](#): Overview of the AFFIRM study, a Phase III trial assessing TYSABRI's impact on relapse rates and disability progression in RRMS patients.
- [TYSABRI Observational Programme](#): Insights into long-term observational data supporting TYSABRI's efficacy and safety.
- [NEDA](#): Discussion on achieving No Evidence of Disease Activity (NEDA) in RRMS patients treated with TYSABRI.
- [Study Information](#): Summary of the AFFIRM study design, primary endpoints, and post-hoc analyses for highly active RRMS patients.
- [Summary of 2-Year Efficacy Data](#): Key findings from the AFFIRM study, highlighting TYSABRI's effectiveness in reducing lesions and relapse rates over two years.
- [References and Abbreviations](#): Definitions of key terms and references for further reading, including ARR, EDSS, and Gadolinium-enhancing lesions.